Monoclonal Antibodies In Veterinary Health Market to Grow with a CAGR of 15.50% through 2030
Increasing Companion Animal Ownership and Pet Humanization and Rising Prevalence of Animal Diseases and Zoonotic Infections are expected to drive the Global Monoclonal Antibodies In Veterinary Health Market growth in the forecast period, 2026-2030
According to TechSci Research report, “Monoclonal
Antibodies In Veterinary Health Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2030F”, the Global Monoclonal
Antibodies In Veterinary Health Market stood at USD 903.40 Million in 2024 and is anticipated to grow with a CAGR of 15.50%
in the forecast period, 2026-2030.
The growing global demand for high-quality meat, dairy, and poultry products has intensified the need for enhanced disease management in livestock. Monoclonal antibodies (mAbs) provide an effective solution to improve productivity, reduce mortality rates, and mitigate economic losses caused by infectious diseases in cattle, swine, and poultry. As a result, these biologics are increasingly recognized as critical tools in modern livestock health management.
Regulatory pressures and concerns over antimicrobial resistance (AMR) have further accelerated the shift away from traditional antibiotics in animal health. Global authorities such as the FDA, EMA, and WHO have implemented stringent regulations to curb antibiotic use in livestock, promoting the adoption of safer and more targeted alternatives like monoclonal antibodies. Unlike antibiotics, mAbs offer precise therapeutic intervention without contributing to AMR, positioning them as a preferred treatment for bacterial infections in animals.
Meanwhile, advancements in biotechnology, genetic engineering, and recombinant DNA technology have significantly enhanced the development, efficacy, and specificity of veterinary monoclonal antibodies. Innovations such as chimeric and fully humanized antibodies have improved target selectivity and minimized immunogenic responses in animals, driving greater adoption in the market. These technological breakthroughs are expanding the potential applications of mAbs in veterinary medicine, reinforcing their role in next-generation animal healthcare solutions.
Additionally, pharmaceutical companies and biotech startups are making substantial investments in veterinary monoclonal antibody research and development. Strategic partnerships, mergers, and acquisitions are fostering innovation, enabling companies to expand their biologics portfolios and secure regulatory approvals for novel mAb therapies. As demand for specialized veterinary treatments continues to rise, industry leaders are focusing on accelerating product launches and strengthening their foothold in the rapidly evolving veterinary biopharmaceutical sector.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Monoclonal Antibodies In Veterinary Health Market”
The Global Monoclonal Antibodies In Veterinary Health Market
is segmented into animal type, application, end-user, regional distribution,
and company.
Based on its end-user, The veterinary hospitals segment holds the largest market share in the Global Monoclonal Antibodies (mAbs) in Veterinary Health Market, driven by rising pet healthcare expenditure, increasing adoption of biologic therapies, and the presence of specialized veterinary professionals. As the primary centers for advanced diagnosis, treatment, and management of chronic and infectious diseases in animals, veterinary hospitals play a crucial role in the widespread adoption and administration of monoclonal antibody therapies. Veterinary hospitals cater to a large and diverse patient base, making them the preferred end users for monoclonal antibody-based treatments. As the first point of contact for complex and severe animal health cases, hospitals see a higher influx of pets and livestock requiring specialized therapies. The presence of multidisciplinary veterinary specialists ensures that hospitals are better equipped to diagnose and manage conditions requiring mAb therapies, such as atopic dermatitis, osteoarthritis, and certain cancers. Advanced diagnostic capabilities, in-house laboratories, and 24/7 emergency care make veterinary hospitals the most suitable facilities for administering monoclonal antibody treatments in a controlled setting. With higher patient volume and specialized treatment infrastructure, veterinary hospitals remain the leading end-user segment in the global market.
Based on region, The Asia Pacific region is projected to fastest market growth in the Global Monoclonal Antibodies in Veterinary Market during the forecasted period. This growth can be
attributed to the emergence of local players in the market, the increasing
number of veterinary hospitals and clinics, and a rising trend in pet
ownership. Furthermore, heightened awareness regarding pet diseases and the
availability of various treatment options are expected to further stimulate
market growth in the Asia Pacific region.
Major companies operating in Global Monoclonal
Antibodies In Veterinary Health Market are:
- Zoetis Inc.
- Merck & Co., Inc.
- Elanco LLC
- Boehringer Ingelheim GmbH
- Indian Immunologicals Ltd
- Virbac SA
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“As technology and research continue to advance, the
future of veterinary healthcare looks promising. The synergy between innovation
in monoclonal antibodies and collaborative efforts within the industry will
ultimately result in improved treatments, better outcomes for animal patients,
and a brighter future for the global monoclonal antibodies in veterinary health
market,” said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“Monoclonal Antibodies In Veterinary Health Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type (Dogs, Others), By Application (Dermatology, Pain, Others), End-User (Veterinary Hospitals, Others), By Region, & Competition, 2020-2030F”, has evaluated
the future growth potential of Global Monoclonal Antibodies In Veterinary
Health Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Monoclonal
Antibodies In Veterinary Health Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com